The US National Institute of Health (NIH) recently launched a study designed to determine whether certain approved therapies or investigational drugs show promise against COVID-19 and merit advancement into larger clinical trials.
Last updated on November 17, 2020, the ACTIV-5 Big Effect Trial, which will enroll adult volunteers hospitalized with COVID-19 at as many as 40 U.S sites, is being conducted in collaboration with the NIH’s public-private partnership Accelerating COVID-19 Therapeutic Innovations and Vaccines (ACTIV) program.
Read More
